Prospective study of low dose rate brachytherapy combined with stereotactic body radiotherapy for very-high risk prostate cancer

Prospective study of low dose rate brachytherapy combined with stereotactic body radiotherapy for very-high risk prostate cancer - Prospective study of low dose rate brachytherapy combined with stereotactic body radiotherapy for very-high risk prostate cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036663

Enrollment

Registered

2019-07-01

Start date

2019-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

radiotherapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) pathologically confirmed adenocarcinoma 2) >=T3b or Gleason socre >=9 3) performance status >=1

Exclusion criteria

Exclusion criteria: 1) active tumor in other organs 2) uncontrolled diabetes 3) Severe concomitant diseases 4) psychiatric disease 5) history of pelvic irradiation 6) history of chemotherapy 7) physician's estimation

Design outcomes

Primary

Measure	Time frame
3-year actuarial Grade 3 toxicity rate	—

Countries

Japan

Contacts

Public ContactHiromichi Ishiyama

Kitasato university school of medicine Department of radiation oncology

hishiyam@kitasato-u.ac.jp042-778-8453

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026